Last reviewed · How we verify

Indium In 111-DOTA-Basiliximab

City of Hope Medical Center · Phase 1 active Small molecule

Indium In 111-DOTA-Basiliximab is a Small molecule drug developed by City of Hope Medical Center. It is currently in Phase 1 development. Also known as: 111In-DOTA-Basiliximab.

At a glance

Generic nameIndium In 111-DOTA-Basiliximab
Also known as111In-DOTA-Basiliximab
SponsorCity of Hope Medical Center
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Indium In 111-DOTA-Basiliximab

What is Indium In 111-DOTA-Basiliximab?

Indium In 111-DOTA-Basiliximab is a Small molecule drug developed by City of Hope Medical Center.

Who makes Indium In 111-DOTA-Basiliximab?

Indium In 111-DOTA-Basiliximab is developed by City of Hope Medical Center (see full City of Hope Medical Center pipeline at /company/city-of-hope-medical-center).

Is Indium In 111-DOTA-Basiliximab also known as anything else?

Indium In 111-DOTA-Basiliximab is also known as 111In-DOTA-Basiliximab.

What development phase is Indium In 111-DOTA-Basiliximab in?

Indium In 111-DOTA-Basiliximab is in Phase 1.

Related